Press-release for stocks for johnson & johnson

entities : Johnson & johnson

save search

Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer
Published: 2024-03-18 (Crawled : 11:00) - globenewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M

Health Technology

| -8.4% | O: 0.2% H: 0.08% C: -1.14%
CLSD | $1.32 4.76% 4.55% 330K

Health Technology

| -32.75% | O: 4.09% H: 0.0% C: -12.36%
medical

World Cancer Immunotherapy Market Research 2023-2027: Curing Cancer is Generating Enormous New Opportunities - Outcome Potential, Technology Environment, Target Solutions
Published: 2024-03-16 (Crawled : 04:20) - prnewswire.com
BIIB | $190.55 -0.84% -0.84% 1.5M

Health Technology

| Email alert Add to watchlist
SNY | News | $45.395 -1.55% -1.58% 4.4M

Health Technology

| Email alert Add to watchlist
JNJ | News | $145.74 0.67% 0.0% 9.3M

Health Technology

| Email alert Add to watchlist
SNYNF | News | $92.7 -2.18% 1.4K

Health Technology

| Email alert Add to watchlist
world cancer research solutions immunotherapy technology market

Register Now for the 7th Annual Digi-Tech Pharma & AI Conference: London, United Kingdom - May 28-29, 2024
Published: 2024-03-15 (Crawled : 23:00) - prnewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M

Health Technology

| Email alert Add to watchlist
pharma

FDA Adcomm Backs J&J’s Carvykti, BMS’s Abecma Early in Multiple Myeloma
Published: 2024-03-15 (Crawled : 23:00) - biospace.com/
JNJ | News | $145.74 0.67% 0.0% 9.3M

Health Technology

| -9.85% | O: -1.58% H: 0.0% C: 0.0%
fda

CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma
Published: 2024-03-15 (Crawled : 21:00) - biospace.com/
JNJ | News | $145.74 0.67% 0.0% 9.3M

Health Technology

| -9.85% | O: -1.58% H: 0.0% C: 0.0%
LEGN | $47.16 -3.42% -3.54% 820K

Health Technology

| -28.72% | O: -0.27% H: 4.91% C: -2.9%
carvykti fda treatment

U.S. FDA Oncologic Drugs Advisory Committee recommends CARVYKTI® (ciltacabtagene autoleucel) for the earlier treatment of patients with relapsed or refractory multiple myeloma
Published: 2024-03-15 (Crawled : 19:00) - prnewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M

Health Technology

| Email alert Add to watchlist
carvykti fda treatment

FDA Adcomm Unanimously Votes in Favor of J&J’s Carvykti Early in Multiple Mye...
Published: 2024-03-15 (Crawled : 19:00) - biospace.com/
JNJ | News | $145.74 0.67% 0.0% 9.3M

Health Technology

| -9.85% | O: -1.58% H: 0.0% C: 0.0%
fda carvykti

Asgard Gets $32M Series A Backing from J&J, Novo and Boehringer
Published: 2024-03-15 (Crawled : 17:00) - biospace.com/
JNJ | News | $145.74 0.67% 0.0% 9.3M

Health Technology

| -9.85% | O: -1.58% H: 0.0% C: 0.0%
series

Oncology Precision Medicine Market Research, Industry Trends and Global Forecasts, 2035 - Rising Partnership and Clinical Trial Activity Reflect Growing Interest in the Market
Published: 2024-03-15 (Crawled : 15:00) - prnewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M

Health Technology

| -9.85% | O: -1.58% H: 0.0% C: 0.0%
partnership precision global trends growing trial market

Madrigal’s Rezdiffra, BMS’s Breyanzi Lead Week of Landmark FDA Approvals
Published: 2024-03-15 (Crawled : 15:00) - biospace.com/
PRGO | $29.94 -0.33% 0.0% 970K

Health Technology

| -2.69% | O: -0.62% H: 0.59% C: -1.01%
JNJ | News | $145.74 0.67% 0.0% 9.3M

Health Technology

| -9.85% | O: -1.58% H: 0.0% C: 0.0%
ABT | News | $105.27 -0.6% -0.15% 7.3M

Health Technology

| -11.37% | O: -5.53% H: 0.0% C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M

Health Technology

| -6.03% | O: -0.02% H: 0.0% C: 0.0%
fda breyanzi week

Monoclonal Antibody (mABs) Therapeutics Market Worth $497.5 billion | MarketsandMarkets™
Published: 2024-03-15 (Crawled : 14:30) - prnewswire.com
TAK | News | $13.16 0.08% 0.0% 1.3M

Health Technology

| -8.3% | O: 0.21% H: 0.97% C: 0.7%
NVS | $92.57 -0.55% 0.0% 910K

Health Technology

| -5.15% | O: 0.05% H: 0.14% C: -0.93%
JNJ | News | $145.74 0.67% 0.0% 9.3M

Health Technology

| -9.85% | O: -1.58% H: 0.0% C: 0.0%
LLY | $745.95 -0.64% -0.1% 1.7M

Health Technology

| -1.31% | O: -0.7% H: 0.73% C: -0.16%
ABBV | News | $164.66 0.25% -0.15% 4.5M

Health Technology

| -8.4% | O: -0.07% H: 0.0% C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M

Health Technology

| -6.03% | O: -0.02% H: 0.0% C: 0.0%
REGN | $893.66 -0.84% -0.84% 450K

Health Technology

| -6.03% | O: -0.27% H: 1.26% C: 0.84%
AMGN | $262.77 -0.49% -0.49% 2M

Health Technology

| -2.43% | O: 0.2% H: 1.14% C: -1.18%
antibody therapeutics market

AstraZeneca, Novartis, Merck Add to 2024 M&A Upswing
Published: 2024-03-15 (Crawled : 13:30) - biospace.com/
JNJ | News | $145.74 0.67% 0.0% 9.3M

Health Technology

| -9.85% | O: -1.58% H: 0.0% C: 0.0%
merck

FDA Adcomm to Tackle Complexity of CAR-T for Multiple Myeloma
Published: 2024-03-15 (Crawled : 13:30) - biospace.com/
JNJ | News | $145.74 0.67% 0.0% 9.3M

Health Technology

| -9.85% | O: -1.58% H: 0.0% C: 0.0%
fda car-t

BMS’s Breyanzi Becomes First CAR-T Therapy for Two Types of Leukemia
Published: 2024-03-15 (Crawled : 12:30) - biospace.com/
JNJ | News | $145.74 0.67% 0.0% 9.3M

Health Technology

| -9.85% | O: -1.58% H: 0.0% C: 0.0%
first breyanzi car-t leukemia therapy

Oral Care Market Size, Share & Trends Analysis Report 2024-2030: Toothpaste & Toothbrush Segments Lead with Rapid Innovation
Published: 2024-03-14 (Crawled : 22:00) - prnewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M

Health Technology

| -9.85% | O: -1.58% H: 0.0% C: 0.0%
CL | $86.71 -0.05% 0.1% 4.8M

Consumer Non-Durables

| -2.47% | O: -1.01% H: 1.51% C: 1.13%
report rapid innovation care trends market

Biopharma Layoff Tracker 2024: Spruce, Coherus, Takeda and More Cut Staff
Published: 2024-03-14 (Crawled : 15:30) - biospace.com/
RLYB | $1.68 -4.55% -4.76% 350K